bpc-157 interstitial cystitis pilot study Pathophysiology and potential multimodal therapeutic strategies for IC/BPS Wellness clinics promote the use

Acta Otorhinolaryngol Ital

Parimon, T

PMID: 20854973 Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Ads LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C

Now the peptide is at the heart of a polarized debate in the United States, one that raises a core question about how the Food and Drug Administration ought to regulate drugs: Should regular Americans be able to access unapproved substances like BPC-157